2013Annual-Report

The annual report.

It’s a requisite exercise in the business world, from the smallest
nonprofit to the largest corporation in the land.The close of a
year brings with it the opportunity to capture a snapshot of the
past 12 months.The numbers.The achievements.The people
who made things happen.

As we discussed potential concepts and elements for OMRF’s
2013 annual report, we toyed with plenty of options.Was ’13
a year of bad luck—or good? A baker’s dozen? Dictionary
publisher Merriam-Webster Inc., named “science” its 2013
word of the year. Definitely up our alley, right? From selfies to
sequestration, 2013 brought with it a jumble of topics and terms
all vying for our attention.

While we considered our options, we asked questions. Lots of
questions. In science, after all, every question generates more
questions. Our list grew and grew.

And soon we realized that our concept was right under our
noses: to answer some key questions that we—and maybe you—
asked this year.

We pared down the list to a nice (un)even 13 and went in search
of the answers.

1

4 Why can’t we keep
people from getting sick?
13
Questions 6 Answered by
for OMRF Stephen Prescott, M.D.

in 2013 8 OMRF President

10 What will happen
if the government keeps
2 cutting research funding?

Rodger McEver, M.D.
Cardiovascular Biology
Research Program
Alvin Chang Chair in
Cardiovascular Biology

Is there a gender
gap in research?

Courtney Griffin, Ph.D.
Cardiovascular Biology
Research Program
Joan Merrill, M.D.
Clinical Pharmacology
Research Program

Are scientists playing
with fire by manipulating

stem cells?

Lorin Olson, Ph.D.
Immunobiology and Cancer

Research Program

12 22How is OMRF different Why isn’t OMRF better
14 from a hospital? known nationally?
16
18 Judith James, M.D., Ph.D. Paul Kincade, Ph.D.
20 Arthritis and Clinical Immunology Vice President of Research
William H. and Rita Bell Chair
Research Program
Lou C. Kerr Endowed Chair in in Biomedical Research

Biomedical Research How hard is it to recruit new
scientists to Oklahoma?
24Do “Eureka!” moments
really exist? Courtney Stevens
Vice President of
Gary Gorbsky, Ph.D.
Cell Cycle and Cancer Human Resources

Biology Research Program When will we
W.H. and Betty Phelps Chair cure cancer?

in Developmental Biology David Jones, Ph.D.
Immunobiology and Cancer
Scott Plafker, Ph.D.
Free Radical Biology and Aging Research Program
Jeannine Tuttle Rainbolt Endowed
Research Program
Chair in Cancer Research
Why use mice for research 26
instead of sick patients? Why do you give to OMRF
when you can’t see
Linda Thompson, Ph.D. the results now?
Immunobiology and Cancer
Paul and Carolyn Schulte
Research Program OMRF Board of Directors
Putnam City Schools Distinguished Chair

in Cancer Research

28When I give a dollar to

OMRF, where does it go?

Tim Hassen
Vice President and
Chief Financial Officer

Why study rare diseases? 2013 in Review, page 30

Patrick Gaffney, M.D. Donor and Financial Information
Arthritis and Clinical Selected Publications, page 34
Best of 2013, page 36
Immunology Research Program Selected Financials, page 37
J.G. Puterbaugh Chair in Honor Roll, page 38
Medical Research Scientific Faculty, page 46
Board of Directors, page 48
Courtney Montgomery, Ph.D.
Arthritis and Clinical Immunology

Research Program

Interviews have been condensed and edited.
Written by Shari Hawkins • Photographs by Brett Deering • Design by Jenny Lee

3

QUESTION ONE

If we know so
much about the
human body,
why can’t we
keep people from
getting sick?

4

“The more we learn about disease, the more
we realize how much we still don’t know.”

OMRF President Stephen Prescott

Steve’s background as a physician gives him keen insight into the importance of research
and its role in improving human health.

“Expectations soared when we launched the Human Ten years ago, the idea of changing a blood cell to a
Genome Project in the 1990s. Diseases, we thought, muscle cell or using your own cells to reconstruct bone
would fall like dominoes. or repair your heart was pure science fiction.Today,
Did mapping the genome reveal all the answers to our regenerative medicine—transforming our own cells into
questions about disease? Hardly. stem cells to renew and restore our bodies—is one of the
Still, we can’t label that effort a failure. Many new hottest topics in research.
therapies have come out of the genome project or are in
the pipeline. It can take 16 or 17 years for a drug to go Still, there’s one factor that lies outside our control:
from the lab to the marketplace, so we aren’t even close the human element. Some people still smoke.We eat
to seeing the final results. unhealthy foods and avoid exercise. Improvements in our
Perhaps we were naïve or overly confident in our behavior would certainly reduce the occurrence of some
ability to find all the answers and create a disease-free diseases, but curbing those behaviors lies beyond the
world. Instead of conquering illnesses outright, we’ve reach of medical research.
learned that diseases, as well as the human body, are
infinitely more complicated than we ever imagined. To deal with complex diseases, we’ll need to pool our
Bacteria and viruses like influenza constantly mutate intellectual resources more effectively.The strength of the
and change themselves to evade our efforts to stop them. discovery process lies in its diversity. Research requires an
We can guess what they’ll do next, but they’re too clever ensemble cast, each player bringing his or her particular
for us to get too far ahead of them. expertise to the table, to the lab, to the clinic.
But, in my professional career as a physician, deaths
from heart attack and stroke have fallen about 60 As our knowledge base continues to grow, I’m
percent, all from improvements in research, surgery and optimistic that we’re on track to keep making inroads
treatments. It didn’t happen overnight, but it did happen, against disease. Maybe not today or even tomorrow.
and millions of lives have been saved as a result.
”But soon.

5

QUESTION TWO

What will
happen if the
government
keeps cutting
funding for
research?

6

“Our entire society will suffer.”

Dr. Rodger McEver

Rod got his start at OMRF in 1965 as a Sir Alexander Fleming Scholar and now leads OMRF’s
Cardiovascular Biology Research Program.

“If these funding cuts continue, some of the most highly We’ve spent decades developing this wonderful medical
educated and well-trained individuals in our country will research infrastructure that has led the world.That
be forced to leave the field. It will be a tremendous waste structure is shrinking and is about to start disintegrating.
of human talent.
When I got my first grant 30 years ago, it wasn’t this Medical research is one of the most competitive
stressful. I spent a lot more time doing science and less programs in the entire federal government.We’re
time writing grants.Today, even strong investigators may doing something valuable with taxpayers’ hard-earned
not get funding.When that happens, labs shrink. Jobs money, but in this current environment, no matter how
disappear.We’re going to lose a generation of remarkable innovative, creative or productive you are, you’ll end up a
people who’ve spent years preparing to foster knowledge. loser. Society will be the real loser.
Research improves the intellectual vibrancy of society
and creates jobs. Medical research is the engine that Expanding the research budget, even modestly,
will help us find answers to human disease.Without will make our society more vigorous, provide more
it, discoveries won’t be made. Jobs won’t be created. opportunities for our young people, foster economic
The intellectual strength of our society will decline. development and improve human health. Cutting it has
Healthcare will not improve.And they’re all linked.We huge and long-lasting negative repercussions. Support for
have an aging population, so we need more medical
research, not less. Our economy is ailing, so we need ”medical research should be a high priority.
more high-quality jobs, not fewer.

7

QUESTION THREE

Is there a gender
gap in research?

8

“Not from where we sit.”

Drs. Joan Merrill and Courtney Griffin

Joan treats lupus patients and conducts clinical trials for new medications for the disease, while Courtney studies blood vessel
development and the genes involved in the process.

“COURTNEY: My experience has been virtually COURTNEY: Those two worlds—the lab and
gender-blind. Some of my biggest cheerleaders are home—complement each other well for me. I can’t
and have been men. imagine doing one without the other.
JOAN: Biases exist in certain areas, but men face JOAN: I was 30 when I entered medical school,
pressures as well. so age played a bigger role in my story than gender.
COURTNEY: I’ve had friends in other professions When it’s your passion, you follow it.You have to
who quit work for a few years to have children. make choices.
Science moves quickly, so there’s no easy on or off COURTNEY: Personality is a much bigger factor
ramp for taking a break and raising a family. Some than gender. I’ve been lucky to have excellent
find they have to choose between having a family or mentors who were truly good people, and that
a career. makes the difference.A lab is a very intimate place.
JOAN: Early in my career, the National Institutes of Now that I’m a mentor myself, I’m very cognizant
Health offered special grants for women re-entering that I’m working with humans, complete people—
the workforce. I was upset. Here I was, working not just men and women.You have to balance what’s
and raising a family all those years. I’d never left the going on in their lives and respect that. It’s a human
workforce.And now I couldn’t qualify to get that
grant money? ”equation, not a gender thing.

9

QUESTION FOUR

Are scientists
playing with fire
by manipulating

stem cells?

10

“Absolutely not.”

Dr. Lorin Olson

In OMRF’s Immunobiology and Cancer Research Program, Lorin studies adult stem cells and how they
can be applied to the process of healing wounds.

“If you had diabetes and doctors told you they could works.Those studies have yielded new treatments
give you new pancreatic cells and possibly cure your for disease and added years to many lives.The notion
disease, would you tell them to stop? Imagine you had of controlling the function of a cancer cell brings
multiple sclerosis, where the cells around your muscle cheers all around. Likewise, people everywhere would
fibers degrade and interfere with the brain’s signals embrace the possibility of improving their brain cells
to the body. If scientists found a way to create new, to reduce the devastating effects of Alzheimer’s disease
healthy muscle cells that might lessen or end your MS or dementia.
symptoms, would you pull the plug on that research?
Of course not. Even if stem cell research doesn’t yield a treatment
Stem cells possess the ability to turn themselves into for a human disease, it’s still valuable to researchers
different types of cells. No longer the stuff of science to help us answer important questions like: How do
fiction, they’ve opened a new research frontier, one of our organs work? And why do we age? Is it because
hope and promise.While it’s foolish to oversell their our stem cells stop maintaining our bodies like they’re
value, most scientists believe stem cells hold great supposed to?
potential for helping us tap into new ways to control
disease, often using our own cells. If we don’t keep studying stem cells and following
For decades, researchers have manipulated human up on the questions they generate, we might never find
cells of all kinds to learn more about how the body
”the answers.

11

QUESTION FIVE

How is
OMRF
different
from a
hospital?

12

“Hospitals provide short-term acute care.
OMRF focuses on the long game: to
understand human health and disease.”

Dr. Judith James

Judith launched her scientific career in 1988 at OMRF, where she continues to study and treat patients with autoimmune diseases.

“OMRF once had a strong tradition of operating a We have strategically decided that we can learn an
hospital with a research focus.At the time, it was the immense amount about many diseases by focusing on
only way we could give chemotherapy treatments or one category: autoimmune diseases.These are conditions
participate in national clinical trials. in which the body turns its disease-fighting arsenal
Many people in Oklahoma still equate OMRF on itself.Autoimmune diseases like lupus, Sjögren’s
with a hospital. But the critical care arena has changed syndrome and multiple sclerosis tend to cluster together
dramatically since those early days. In fact, most current and share similarities but have unique differences.This
medical practices exist on an outpatient basis. Because we allows us to apply different scientific approaches that
focus on chronic, not acute, diseases, we are best aligned might benefit more than just one condition.
as an outpatient facility.
For the diseases we study, many times we can We need to study drugs in patients who are healthy
understand more about our patients’ needs from clinic enough to take them. Our outpatient model is perfectly
visits.That frequent, face-to-face contact helps us learn suited for working with a larger number of people and
a great deal about how our patients manage their disease observing a wide variety of real-life disease presentations.
and how it affects their daily lives. It also lets us learn a
lot about the disease process and help patients manage By focusing on our areas of expertise, we can help
their symptoms in a direct and targeted way. bring new and meaningful treatment options to those

”who need it most.

13

QUESTION SIX

Do “Eureka!”
moments
really exist?

14

“They do. But they’re usually
more of a whisper than a shout.”

Drs. Scott Plafker and Gary Gorbsky

Scott’s research focuses on the role of oxidative stress in age-related macular degeneration. Gary studies cell
division and how changes in that process can lead to the development of cancer.

“GARY: A true ‘Eureka!’ moment happens when you SCOTT: Sometimes we can learn more from a negative
get a result and it’s immediately crystal clear where result than we can from one we expected from the start.
you’ve been wrong up to that point. It’s the instant you That’s a pivotal moment, albeit a quieter one.
figure out something the entire field has missed. It’s very GARY: Research is a never-ending process. But each
rare but very important. step takes you to a new place of understanding.There’s
SCOTT: Yeah, it’s when everything clicks into place. always a bit of mystery that lingers.
When your previous 10 or more results finally make SCOTT: Even a great idea can require a long time
sense.You see what you were missing.The ‘Eureka!’ part before it can be tested. It’s kind of like cooking. Say you
happens with the awareness that the answer was right decide to make cookies, but you have to create them
in front of you the whole time, in plain sight. But until from nothing. So you grow the wheat and grind it for
then, you weren’t thinking about it or interpreting it in flour.You make the chocolate for the chips. Need sugar
the way that let you see the answer. and butter? You have to gather or create those, too.
GARY: Few of those moments occur alone, though. GARY: Sometimes you have to build the oven.And the
Working with the people in the lab, bouncing ideas baking pan.
around, building on each other’s strengths. It’s really a SCOTT: It’s so complicated. Definitely no instant
social event. gratification. But when you’ve gathered the ingredients,
SCOTT: True. It’s often about ongoing interpersonal mixed them, baked them, and you take a bite of that
interactions with outstanding colleagues.That’s the great cookie—and your experiment works—it makes that
thing about OMRF. It’s a really special environment.
GARY: Early in my career, I had what I considered a ”moment that much sweeter.
real breakthrough. But instead of running through the
lab showing everyone, I just did more experiments. I had
to prove that what I’d found was real.

15

QUESTION SEVEN

If you’re
interested
in curing human
disease,why
use mice for
research instead
of sick patients?

16

“There’s a limit to the kinds of
experiments we can do with humans.
I mean, people are complicated.”

Dr. Linda Thompson

Much of Linda’s research on the human immune system started with findings gathered from the offspring of Hope, a mouse
her lab genetically engineered.

“Some diseases are very hard to study in a human, Human clinical trials can cost millions of dollars,
so mice help us learn faster and without safety risks and still, in the end, most drugs fail.We need a way to
associated with human studies. Mice breed quickly narrow our choices for new drugs and test them in
(every 19 days), and we have good information on many animals before trying them in humans.To skip animal
of their important genes, similar to what we have on studies and jump directly to human studies wouldn’t be
human genes. safe. And who would volunteer?
Complex human diseases often result from interactions
between different genes. Scientists have sequenced the We keep our mice in a very controlled environment,
entire mouse and human genomes, and those data are so we can eliminate many environmental factors, as well.
very powerful. In a human population, where every We can control their stress levels, the food they eat and
person is different and has a unique genetic makeup, it is their exposure to infectious agents. In humans, that level
very challenging to study almost any disease, especially of control would be virtually impossible.
those where multiple genes are involved.
In the lab, we use genetically inbred strains of mice, No, it’s not a perfect system. But it’s just not practical
so every mouse has exactly the same genes. Because of to try a lot of interventions in humans without doing
that, we are able to manipulate their genetic makeup something in an animal model first.
down to one single gene.We can put in new genes,
knock genes out or make different forms of genes and For my area of research, there’s just no other biological
observe the results in an animal model.You just can’t do system that would give me better results than I can get
that in humans. with mice.

”The mouse is king.

17

QUESTION EIGHT

When I give
a dollar
to OMRF,
where
exactly does
it go?

18

“Every gift OMRF receives is used to
further the cause of medical research.”

Tim Hassen

As Vice President and Chief Financial Officer, Tim manages OMRF’s money, whether it flows in or out.

“Many gifts come to us earmarked or designated we say, our researchers understand that we’re all
to a specific research area, like cancer or lupus or working for the greater good of the institution.
heart disease.A full 100 percent of designated gifts
go to that specific research area and nowhere else. Our exceptional ranking with Charity
We spend a lot of time and effort and accounting Navigator assures our donors that we run a
to make sure that’s actually true.We take that task tight ship, that our governance policies are good
very seriously. and that our accounting policies are sound.
Undesignated gifts go into a general fund and We consistently receive clean audits, and our
offer us great flexibility.They can be used to buy administrative expenses stay quite low.
laboratory equipment, cover a scientist’s salary or
any of hundreds of other purposes.Those funds It’s not easy, but we’re always looking for ways to
allow us to focus on areas that need attention most. be more efficient and effective. It’s in the front of
At the end of the day, we’re here to help our our minds all the time: how to grow the science
scientists focus on research.We still function as without increasing our administrative side. Science
overseers or gatekeepers when it comes to money,
so we’re not always the most popular people at ”takes priority.Always.
OMRF. But even when they don’t like what

19

QUESTION NINE

Why study a rare
disease when
you could be
trying to tackle
a big one like
heart disease or
Alzheimer’s?

20

“Rare diseases can help us
answer questions about the basis
of all diseases.”

Drs. Patrick Gaffney and Courtney Montgomery

Patrick, a physician, has identified the gene for a rare condition known as Adams-Oliver syndrome. Courtney, a biostatistician,
focuses a portion of her research on sarcoidosis, a rare immune disease in African-American patients.

“As researchers, we focus on identifying the removing or “knocking out” a gene from a mouse’s
processes that lead to disease, regardless of what we DNA, we can observe how the animal’s overall
call it.The more we learn about any condition, the health is affected by the gene’s absence.We just can’t
more likely we are to find parallels to other disease do that with humans. But Mother Nature can. Rare
areas along the way. disorders tend to function as nature’s knockouts,
Neither of us set out to focus on the conditions unusual occurrences of disease little known to
we study today. Instead, we followed the research scientists or physicians.
where our interests took us. It doesn’t matter what
they’re called—they’re all complex problems and all Why do we study rare diseases? To understand how
equally difficult. genes work.We’re seeking the truth, regardless of the
But in the lab, we hope to identify the specific condition.And as scientists, we have to stay flexible
genetic changes that cause a particular condition and curious, forever training, forever learning and
and how they’re unique or whether they might span remain willing to move in whatever direction the
across diseases.
We focus on genes, because of their influence on ”discoveries take us.
human health and behavior.We often use mice to
study the way genes work in a living creature. By

21

QUESTION TEN

Why isn’t OMRF
better known
nationally – like
St. Jude’s or the
Mayo Clinic?

22

“We’re very well known to one
particular audience: scientists.”

Dr. Paul Kincade

Recognized as a star in immunology circles, Paul now shares his experience with all of
our scientists as OMRF’s Vice President of Research.

“When I came here from NewYork in 1982, I had association with Dust Bowl days. But our community
never heard of OMRF or Oklahoma City. Some of truly appreciates and takes a genuine interest in what
my friends thought there was nothing but wilderness we do.They revel in our successes with us.They know
from the East River all the way to California. It was a important things happen here.
mystery to them when I found myself looking at a job
at an institution I knew nothing about in a completely For scientists, there are distinct advantages in pursuing
unknown city. a career in a smaller place like OMRF. While others
OMRF had no celebrity spokesperson. No nationwide may boast of Nobel Prize winners and huge teams of
fundraising programs. But something seemed special to researchers, for a young investigator, it’s hard to make a
me as I visited this land-locked research foundation.And name for yourself in that environment. In a smaller pond
it was. like OMRF, you can be a bigger duck.You can get credit
I soon left a large, well-known institution (Memorial for what you do and build a reputation that allows you
Sloan-Kettering Cancer Center) to start a new phase to compete for grants. People will notice you.And when
of my career at OMRF, and I didn’t lose a thing in the you do good work, they also will notice where you
process.The bigger place provided no better labs or come from.
resources than those I enjoyed for the next three decades
here at OMRF. OMRF competes well against huge, well-funded
It’s difficult to compare institutions and cities, because teams of scientists. Do we need to be bigger, too? Not
they’re all different. But one key to success is for the in a colossal way, and not to grow for growth’s sake.We
institution to adapt to its surroundings. OMRF’s simply need the right people with the right talents and
biggest challenge may be geography or our state’s expertise who will work together to answer important
questions about disease.That’s how people will learn

”who we are.
23

QUESTION ELEVEN

How hard is
it to recruit
new scientists
to Oklahoma?

24

“It’s a lot easier now that
Oklahoma City is known for more
than just natural disasters.”

Courtney Stevens

Courtney joined OMRF’s Human Resources Department in 2003 and became Vice President
in 2013.

“ Oklahoma City has been spotlighted as one of the One question always comes up:What about tornadoes?
most livable cities in the US, and the Thunder basketball Unless they’re from the Midwest or another area prone
team’s success has really put us on the map. OMRF’s to storms, they always ask. But it’s a legitimate question.
multiple rankings as a “best place to work” definitely help If I was going to move to California, I’d worry about
us, and we make sure every recruit is aware of them. earthquakes.And, hey, now we have both!
Advances in technology have helped change
perceptions of Oklahoma, too. People no longer come But the recruiting doesn’t end once they come to
here expecting a “Wild West” atmosphere.We really are OMRF.We can’t stop that wooing process. Our scientists
a hip, happening city, much like any other metropolitan are attractive recruits for other institutions, so it’s up to us
area, and we have a lot to offer.Arts festivals. Live music. to keep them happy enough to want to stay here. So in a
Museums. Sporting events. Nightlife. Diversity.We have way, we have to re-recruit them as we go.
it all.
As recruiters, we’re all about customization. People I think we’re successful because OMRF and Oklahoma
want to know the basics, but we tailor itineraries to a City are everything we’ve promised.We do a good job
person’s specific needs.We want to show them those of giving them a real picture of what it’s like here. No
pieces of the city that will help them maintain their sugar-coating. Just a genuine and realistic picture.We
hobbies and their lifestyle here. Our weather is great never oversell, but we don’t undersell, either. I’d say we’ve
most of the time, so there’s a lot of opportunity for done a good job with that, because the people we recruit
outdoor adventures. Schools are a big deal, especially for
families, so we set up school visits. Our low cost of living ”tend to stick around.
is always a pleasant surprise.

25

QUESTION TWELVE

When will
we cure
cancer?

26

“We’ve already cured some cancers. But cancer
isn’t just one disease, so our definition is flawed.”

Dr. David Jones

Dave joined OMRF in 2013 as the new chair of OMRF’s Immunobiology and Cancer Research Program.

“When man landed on the moon,Americans thought cancer cells as those whose original fate has changed.
we could conquer anything. Cancer included. But This ‘mis-fating’ occurs when the signals that tell a cell
curing cancer is much harder than landing on the to die don’t reach the cell. So it continues to grow and
moon, because back then, we had a very simplistic divide. It becomes a hybrid of sorts, stuck in division
understanding of what cancer was. It took decades mode.That cell is not inherently evil; it simply doesn’t
for scientists to learn that cancer isn’t just one disease; know that it’s doing anything wrong.
it’s dozens of them. Curing cancer actually means
eradicating around 50 diseases or more. One drug, one Cancer happens when that signaling or programming
effort, one focus; that simply won’t get us there. goes awry. If we could erase that bad programming and
But if we step back for a moment, reality tells us that reset cancer cells to their original fate, the cancer could
we can actually cure very few diseases now.We only stop. But mutations and inherited traits all complicate
manage them. People with high blood pressure or at our efforts to fully understand it.
risk of a heart attack take daily medication to treat
those conditions. Still, their heart and blood pressure are Answering the question of ‘When will we cure
never normal.Their diseases aren’t cured.They’re just cancer?’ requires recalibrating people’s expectations about
controlled. If you can manage a disease for years, that’s the disease.Will it be cured versus managed? Will it take
almost as good as a cure, wouldn’t you say? one discovery or more? The answer is: It’s going to take
Cancer cells aren’t that different from the normal many new findings.
cells in the body, so we have to think about them very
precisely and in entirely new ways. In my lab, we study We’re making dramatic improvements in treating and
dealing with cancer.The key is to not think about cancer
as an ‘it’ but instead to think of it as ‘they’ or ‘those.’And

”we’ll pick them off, one at a time.

27

Why do youQUESTION THIRTEEN
keep giving to
OMRF when you
can’t see the
results now?

28

“We want to be a part of something that
improves the quality of life, whether it
happens now or years from now.”

Paul Schulte

Paul joined OMRF’s Board of Directors in 1993. He and his wife, Carolyn, make their home in Kingfisher.

“I grew up on a wheat farm in Kingfisher County. For important to everyone. Its mission of helping people live
as long as I can remember, my parents supported OMRF. longer, healthier lives generates a spirit of cooperation
They taught me that giving to others mattered, and I saw and progress that’s unique and one that also blends
it played out all over rural Oklahoma. perfectly with the Oklahoma spirit.
My parents never went to college, but they recognized
the value of medical research in a most personal way. Farmers always strive to leave the land better than they
My dad suffered from polio as a child, and he witnessed found it. It’s an obligation they happily pay in respect
the advent of a cure during his lifetime. Research, he to their predecessors and as a gift to those who follow
and others of his generation readily acknowledged, was after them. Rural Oklahomans, particularly farmers
instrumental in that cure. and ranchers, are sensitive to the cycle of life.They
I’m excited to be a witness to what OMRF does from know how that cycle can suffer or benefit from outside
a research perspective and also how it advances the image influences. Maybe that’s why they put their faith in
of our state. I can’t think of another institution that OMRF. I know I do.
embodies the spirit of Oklahoma any more than OMRF
does. It attracts people from all walks of life and rivals Progress gained from medical research can extend and
of all stripes—Democrats, Republicans, OU fans, OSU enhance that life cycle.And when research improves the
fans, liberals and conservatives.They come together here.
Hatchets are buried, because when OMRF succeeds, it’s ”life of just one person, it impacts us all.

29

2013 In Review APRIL

JANUARY In a paper published
and highlighted with
Drs. Ken Smith and Judith James used a process a commentary in the
developed at OMRF to find a new way to fight journal Genetics, OMRF
pneumococcus bacteria—a major cause of pneumonia, researcher Dr. Kenneth
ear infections and meningitis. In a paper published in Miller described how
the journal Immunobiology, they explained how they’d unc-16, a gene humans
created the kinds of antibodies a healthy immune share with tiny
system makes after receiving the vaccine. In the future, roundworms called C.
this finding could be used to treat patients with elegans, may act as a kind
pneumonia while the antibiotics begin to work. of “gatekeeper” that
keeps cellular order in
FEBRUARY the nerve cells.

Dr. Dean Dawson’s paper in Science showed how new
“master regular” genes control cell division, a discovery
that has important implications for preventing both
cancer and birth defects.

MARCH MAY

A new $7.8 million grant OMRF selected 40
from the National Institutes Oklahoma students
of Health will help five for the inaugural Teen
OMRF scientists studying Leaders in Philanthropy
cancer, diseases of aging and class. Students from
other illnesses jump-start 18 metro and area
new projects over the next high schools came to
five years.The grant will OMRF each month
also support institutional during the academic
core facilities and create an year to learn the
Institutional Development basics of development,
Award (IDeA) Center networking and non-
of Biomedical Research profit management.
Excellence at OMRF.
JUNE

OMRF scientist Dr. Susannah Rankin received a new
grant from the National Institutes of Health to study how
chromosomes are packaged during cell division.This work
will help scientists understand processes that are crucial to
human development.

30

JULY OCTOBER

We recruited Dr. David Jones, An international coalition
an internationally recognized of researchers led by Dr.
expert in colon cancer and Kathy Sivils identified
personalized medicine, from six new genes related to
the University of Utah to lead the autoimmune disease
the expansion of OMRF’s Sjögren’s syndrome.
cancer research programs.
OMRF scientist Dr. Paul
Kincade found what may
amount to a “fountain of
youth” for adult stem cells.
The discovery could have
implications in reducing age-
related illness from infection.

AUGUST NOVEMBER

OMRF launched its first-ever A new five-year grant will
clinical trial for Oklahoma support research at OMRF
cancer patients.That trial gives and a consortium of other
patients suffering from a deadly institutes to understand
form of brain cancer access to the cause and find new
an experimental drug developed therapies for bleeding
at OMRF. The watershed trial disorders. OMRF scientist
comes as a result of a partnership Dr. Charles Esmon will
between OMRF and the serve as a part of the
Stephenson Cancer Center at the Trans-Agency Consortium
University of Oklahoma. for Trauma-Induced
Coagulopathy, or TACTIC,
SEPTEMBER which will examine why
bleeding becomes an
Working with OU, unmanageable problem for
OSU and tribal health some trauma patients.
authorities, Dr. Judith James
secured a major grant that DECEMBER
will help deliver more
effective care to patients in Dr. Holly Van Remmen joined our scientific staff from
rural Oklahoma. the University of Texas-San Antonio.An expert in
Dr. Lijun Xia and his colleagues discovered the process neuromuscular disorders that affect the aging population,
that allows lymphocytes to exit blood vessels without her research focuses on extending and improving a
releasing red blood cells.The findings, which were person’s “healthspan.”
published in the journal Nature, could help doctors
treat traumatic injuries and serious infections.

31

Impact in 2013

5,705 127 30

Number of active Number of clinical trials
research grants underway—29 for new
medications and 1 in
Number of patient 150 physical therapy
visits to OMRF’s
Multiple Sclerosis Number of scientific
Center of Excellence publications

OMRF employees represent 32 countries

32

113,800 -80˚C
Pounds of dry (or -112 F)
ice used in
OMRF labs The temperature in OMRF’s
Biorepository, an ultra-cold storage
Number of facility that preserves vital scientific
students samples from thousands of patients with
we trained autoimmune diseases.

3 John H. Saxon Service Total Capacity:
More than 5 million samples
Academy Summer
Research Program Current repository samples: 1,012,300
Students
From 1981 – 2013, we have collected
4 Presidential scholars samples from more than:
• 200 multiple sclerosis patients
9 • 800 fibromyalgia patients
Fleming scholars • 3,445 sarcoidosis patients
• 6,000 lupus patients
• 10,000 healthy controls
33 graduate students • 65,000 Clinical Immunology

38 postdoctoral fellows Reference Laboratory samples
40 Teen Leaders
Clinical & research studies
in Philanthropy supported: 53

10,971
Gifts honoring 7,566 people
through donations to OMRF

33

Selected Publications

Aggarwal R, Sestak AL, Chakravarty EF, Dozmorov I, Dominguez N, Sestak AL,
Harley JB, Scofield RH. Excess female Robertson JM, Harley JB, James JA,
siblings and male fetal loss in families with Guthridge JM. Evidence of dynamically
systemic lupus erythematosus. J Rheumatol dysregulated gene expression pathways
40:430-434, 2013. in hyperresponsive B cells from African-
American lupus patients. PLoS One
Chakravarty E, Michaud K, Katz R, 8:e71397, 2013.
Wolfe F. Increased incidence of herpes
zoster among patients with systemic lupus Guiraldelli MF, Eyster C,Wilkerson JL,
erythematosus. Lupus 22:238-244, 2013. Dresser ME, Pezza RJ. Mouse HFM1/
Mer3 Is required for crossover formation
Crewe C, Kinter M, Szweda LI. Rapid and complete synapsis of homologous
Inhibition of pyruvate dehydrogenase: an chromosomes during meiosis. PLoS Genet
initiating event in high dietary fat-induced 9:e1003383, 2013.
loss of metabolic flexibility in the heart.
PLoS One 8:e77280, 2013. Herzog BH, Fu J,Wilson SJ, Hess PR,
Sen A, McDaniel JM, Pan Y, Sheng M,
Deshmukh US, Bagavant H.When killers Yago T, Silasi-Mansat R, McGee S, May F,
become helpers. Sci Transl Med 5:195fs29, Nieswandt B, Morris AJ, Lupu F, Coughlin
2013. SR, McEver RP, Chen H, Kahn ML, Xia
L. Podoplanin maintains high endothelial

34

venule integrity by interacting with Kim S, Meyer R, Chuong H, Dawson induced osteoarthritis with very high-fat
platelet CLEC-2. Nature 502:105-109, DS. Dual mechanisms prevent premature diet.Ann Rheum Dis 72:300-304, 2013.
2013. chromosome segregation during meiosis.
Genes Dev 27:2139-2146, 2013. Rindler PM, Plafker SM, Szweda LI,
Hinks A, Cobb J, Marion MC, Prahalad S, Kinter M. High dietary fat selectively
Sudman M, Bowes J, Martin P, Comeau Liu H, Rankin S,Yu H. Phosphorylation- increases catalase expression within cardiac
ME, Sajuthi S,Andrews R, Brown M, enabled binding of SGO1-PP2A to mitochondria. J Biol Chem 288:1979-
Chen WM, Concannon P, Deloukas P, cohesin protects sororin and centromeric 1990, 2013.
Edkins S, Eyre S, Gaffney PM, Guthery cohesion during mitosis. Nat Cell Biol
SL, Guthridge JM, Hunt SE, James JA, 15:40-49, 2013. Rusakiewicz S, Nocturne G, Lazure T,
Keddache M, Moser KL, Nigrovic PA, Semeraro M, Flament C, Caillat-Zucman
Onengut-Gumuscu S, Onslow ML, Rose Lessard CJ, Li H,Adrianto I, Ice JA, S, Sene D, Delahaye N,Vivier E, Chaba K,
CD, Rich SS, Steel KJ,Wakeland EK, Rasmussen A, Grundahl KM, Kelly JA, Poirier-Colame V, Nordmark G, Eloranta
Wallace CA,Wedderburn LR,Woo P, Dozmorov MG, Miceli-Richard C, ML, Eriksson P,Theander E, Forsblad-
Boston Children’s JIA Registry, British Bowman S, Lester S, Eriksson P, Eloranta d’Elia H, Omdal R,Wahren-Herlenius M,
Society of Paediatric and Adolescent ML, Brun JG, Goransson LG, Harboe E, Jonsson R, Ronnblom L, Nititham J,Taylor
Rheumatology (BSPAR) Study Group, Guthridge JM, Kaufman KM, Kvarnstrom KE, Lessard CJ, Sivils KL, Gottenberg JE,
Childhood Arthritis Prospective Study M, Jazebi H, Graham DS, Grandits ME, Criswell LA, Miceli-Richard C, Zitvogel
(CAPS), Childhood Arthritis Response to Nazmul-Hossain AN, Patel K,Adler AJ, L, Mariette X. NCR3/NKp30 contributes
Medication Study (CHARMS), German Maier-Moore JS, Farris AD, Brennan MT, to pathogenesis in primary Sjögren’s
Society for Pediatric Rheumatology Lessard JA, Chodosh J, Gopalakrishnan syndrome. Sci Transl Med 5:195ra96, 2013.
(GKJR), JIA Gene Expression Study, R, Hefner KS, Houston GD, Huang
NIAMS JIA Genetic Registry,TREAT AJ, Hughes PJ, Lewis DM, Radfar L, Smith K, Muther JJ, Duke AL, McKee E,
Study, United Kingdom Juvenile Rohrer MD, Stone DU,Wren JD,Vyse TJ, Zheng NY,Wilson PC, James JA. Fully
Idiopathic Arthritis Genetics Consortium Gaffney PM, James JA, Omdal R,Wahren- human monoclonal antibodies from
(UKJIAGC), Bohnsack JF, Haas JP, Herlenius M, Illei GG,Witte T, Jonsson R, antibody secreting cells after vaccination
Glass DN, Langefeld CD,Thomson W, Rischmueller M, Ronnblom L, Nordmark with Pneumovax(R)23 are serotype
Thompson SD. Dense genotyping of G, Ng WF, for UK Primary Sjogren’s specific and facilitate opsonophagocytosis.
immune-related disease regions identifies Syndrome Registry, Mariette X,Anaya Immunobiology 218:745-754, 2013.
14 new susceptibility loci for juvenile JM, Rhodus NL, Segal BM, Scofield RH,
idiopathic arthritis. Nat Genet 45:664-669, Montgomery CG, Harley JB, Sivils KL. Sun D, Popescu NI, Raisley B, Keshari
2013. Variants at multiple loci implicated in both RS, Dale GL, Lupu F, Coggeshall KM. B.
innate and adaptive immune responses are anthracis peptidoglycan activates human
Hu T,Wang H, Simmons A, Bajana S, associated with Sjögren’s syndrome. Nat platelets through FcgammaRII and
Zhao Y, Kovats S, Sun XH,Alberola-Ila J. Genet 45:1284-1292, 2013. complement. Blood 122:571-579, 2013.
Increased level of E protein activity during
invariant NKT development promotes Lupu C, Herlea O,Tang H, Lijnen RH, Towner RA, Jensen RL,Vaillant B,
differentiation of invariant NKT2 and Lupu F. Plasmin-dependent proteolysis of Colman H, Saunders D, Giles CB,Wren
invariant NKT17 subsets. J Immunol tissue factor pathway inhibitor in a mouse JD. Experimental validation of 5 in-silico
191:5065-5073, 2013. model of endotoxemia. J Thromb Haemost predicted glioma biomarkers. Neuro Oncol
11:142-148, 2013, 2013. 15:1625-1634, 2013.
Huang H, Chen HW, Evankovich J,Yan
W, Rosborough BR, Nace GW, Ding Merrill JT. Co-stimulatory molecules Wang S,Wen F,Wiley GB, Kinter MT,
Q, Loughran P, Beer-Stolz D, Billiar TR, as targets for treatment of lupus. Clin Gaffney PM.An enhancer element
Esmon CT,Tsung A. Histones activate the Immunol 148:369-375, 2013. harboring variants associated with systemic
NLRP3 inflammasome in Kupffer cells lupus erythematosus engages the TNFAIP3
during sterile inflammatory liver Injury. J Meyer RE, Kim S, Obeso D, Straight PD, promoter to influence A20 expression.
Immunol 191:2665-2679, 2013. Winey M, Dawson DS. Mps1 and Ipl1/ PLoS Genet 9:e1003750, 2013.
Aurora B act sequentially to correctly
Ingram KG, Curtis CD, Silasi-Mansat orient chromosomes on the meiotic Yao L,Yago T, Shao B, Liu Z, Silasi-Mansat
R, Lupu F, Griffin CT.The NuRD spindle of budding yeast. Science R, Setiadi H, Lupu F, McEver RP. Elevated
Chromatin-remodeling enzyme CHD4 339:1071-1074, 2013. CXCL1 expression in gp130-deficient
promotes embryonic vascular integrity by endothelial cells impairs neutrophil
transcriptionally regulating extracellular O’Conor CJ, Griffin TM, Liedtke W, migration in mice. Blood 122:3832-3842,
matrix proteolysis. PLoS Genet Guilak F. Increased susceptibility of Trpv4- 2013.
9:e1004031, 2013. deficient mice to obesity and obesity-

35

12 6 Our rank among large companies in
Number of consecutive “The Oklahoman” newspaper’s list
years OMRF has of “Top Oklahoma Workplaces for
received the highest 2013.” Employees surveyed graded
possible rating from their workplaces in areas such as
CharityNavigator.org, the the employer’s direction, connection
nation’s and execution, as well as their own
largest feelings about their work, manager
charity and pay and benefits.
evaluator.

OMRF’s place on “The Scientist” 7
magazine’s list of the 20 “Best Places
to Work in Academia.” Those on the
list include institutions from across
the United States. The rankings were
based on surveys that gathered more
than 1,200 responses from scientists
across the country.

3 Where we ranked in “The What a gift! “The
Scientist” magazine’s Street,” a national
annual list of the “Best online investing
Places to Work for and financial news
Postdocs.” For the third site, named OMRF
year in a row, OMRF made as one of its “10
this prestigious list. This Best Charities for
year the foundation ranked Christmas 2013.”
third best among U.S. and Only six other
some international research charities topped
institutions in nine different OMRF in the
core areas including quality overall rankings.
of facilities, training,
communication, and pay
and benefits.

36

Selected Financials

OKLAHOMA MEDICAL RESEARCH FOUNDATION
SELECTED FINANCIAL INFORMATION - OPERATING FUND

2012-2013 Prior year

OPERATING REVENUE: $ 29,271,848
7,559,352
Competitive research grants: 36,831,200

National Institutes of Health grants $ 27,314,110 6,871,846
677,300
Other competitive research grants 6,470,648
2,287,906
Total grants 33,784,758 755,613

10,592,665

Private contributions: 1,494,341
1,354,395
Income and gifts from trusts 6,860,429 1,353,847

Gifts & bequests 635,344 498,469
892,611
Contributions 1,901,439 (249,490)
1,117,460
Memorials 755,710 6,461,633

Total private contributions 10,152,922 53,885,498

8,849,536

Other revenue: 62,735,034

Clinical revenue, net of provisions for 47,877,133
4,589,765
contractual and other adjustments 3,091,109 4,583,880
57,050,778
Interest and investment income 1,358,721
$ 5,684,256
Mineral income 1,183,571

Rent 499,780

Royalties and licensing income 384,216

Loss on disposal of assets 62,164

Other 1,440,557

Total other revenue 8,020,118



Total revenue 51,957,798



Operating revenue from wills, pledges, and other restricted gifts

recorded in prior years 5,440,188



TOTAL OPERATING REVENUE 57,397,986



OPERATING EXPENSES:

Program Services - Research 45,628,999

Program Services - Clinic Operations 6,374,088

Support Services - General and administrative 3,958,264

Total operating expenses 55,961,351



EXCESS OF REVENUES OVER EXPENSES $ 1,436,635

37

OMRF Honor Roll
Between January 1 and December 31, 2013, more than 6,000 individuals, corporations, foundations and organizations made gifts and pledges to OMRF.
Each one of those donations made a difference. In this Honor Roll, we have recognized gifts of $500 and above.Your generosity makes life-saving
discoveries possible.

$5,000,000 + Richard K. and Ruth S. Lane Memorial Trust
Love Family Affiliated Fund – OCCF
Chapman Charitable Trusts Mrs. Dimple C. Mobbs
Mr. and Mrs. Lew O.Ward
$1,000,000 - $4,999,999
$10,000 - $24,999
E. L. and Thelma Gaylord Foundation
New Source Energy Corporation Elizabeth and Greg Allen
Sarkeys Foundation Allen Family Charitable Foundation
American Fidelity Foundation/American Fidelity Assurance Company
$100,000 - $999,999 Anonymous
Linda and Lance Benham
David J. Chernicky Mr. and Mrs.Todd Best
Choctaw Nation of Oklahoma Biogen Idec
The Dillingham Family Elizabeth and G.T. Blankenship
Ann Gibbons Trust Mr. and Mrs. Charlie K. Bowen
Gooch Hill Testamentary Trust Mr. and Mrs. Harold E. Brown
The Hocker Foundation Kim E. and Steve Bruno
George W. and Valeria G. Howard Trust Becky and Jim C. Buchanan
Mary Beverly Kobel Trust Mr. and Mrs. Merrill B. Burruss, Jr.
Marvin and Ruth Lebow Medical Research Foundation Cleo Craig Memorial Cancer and Research Foundation – OCCF
The J. E. and L. E. Mabee Foundation, Inc. Devon Energy Corporation
McCasland Foundation Christy and Jim Everest
Presbyterian Health Foundation Hal French
Puterbaugh Foundation Frontiers of Science Foundation of Oklahoma, Inc.
Records-Johnston Family Foundation, Inc. Estate of Albert Wayland Green
United Way of Central Oklahoma Growing the Vision of Light Foundation
The Anne and Henry Zarrow Foundation Harris Foundation, Inc.
G. Ed Hudgins Family Fund – OCCF
$50,000 - $99,999 Inasmuch Foundation
Herman G. Kaiser Foundation
The Anschutz Foundation Jane F. and John A. Kenney
The Chickasaw Nation Jessie Dearing Kinley Testamentary Trust
Wilma Davis-McElmurry Trust Kirkpatrick Foundation, Inc.
Clyde R. Evans Charitable Trust Jay and Sara Kyte
Dr.William D. Hawley Dr. Bill P. Loughridge
John D. Karr Trust Mr. and Mrs. Robert Margo
The Kerr Foundation, Inc. Nadine and Frank McPherson
Mr. Dale Matherly Midtown Renaissance
Matherly Mechanical Contactors, Inc. Lou Ann and Jim Morris
Katie and Aubrey McClendon NBC Oklahoma
Glenn W. Peel Foundation OMRF Fleming Scholarship – OCCF
Susan and Stephen Prescott OMRF General Research – OCCF
Putnam City Schools Cancer Fund Order of the Eastern Star Oklahoma Grand Chapter
Estate of Kuni J. Rankins Simmons Charitable Foundation
Dr. John H. Saxon, III Betty and Charles O. Smith
Estate of Lora Jean Wohlford Teva Pharmaceuticals
Estate of Evelyn Wynell Woodruff Mrs. Norma F.Townsdin
Virginia Zimmerman Trust Traci and Gregory F.Walton
Ms. Jane A.Weber
$25,000 - $49,999 Mr. and Mrs. Paul A.Wege
Mrs. Nancy Wienecke
Hildegarde Suzy Carter Revocable Trust Linda B. and Don A.Wiens
Chesapeake Energy Corporation Mrs. Frances E.Wilson
MS Bridge Fund
Cresap Family Foundation
Susan and Ramsey Drake
Virginia and John Groendyke
Carl E. Gungoll Exploration, LLC

38

$5,000 - $9,999 Carolyn and Paul I. Schulte
The Jack O. Scroggins Charitable Foundation
Mr. Steven C.Agee Paul and Jane Stasbaugh Family Trust
Judy and Winford Akins United Mechanical, Inc.
Ann Simmons Alspaugh Mr. David Watts
Anonymous Mrs. Naomi Welty
Arvest Bank Jodi and Steve Wilsey
Asbury Medical Supply, LLC Barbara D. and Stephen F.Young
Bank of Oklahoma/Bank of Oklahoma Foundation
Miss Betsy L. Barnes $1,000 - $4,999
Louise G. and Clay I. Bennett
Best Companies 7-Eleven, LLC
Mr. David Bishop Acorda Therapeutics, Inc.
Dee-Dee and Bart Boeckman Ms. Mary Evelyn Adams
Mrs. Patty Bryan Mr. Mike G.Adams
Mr. and Mrs. Len B. Cason Judith and Jean Pape Adams Charitable Foundation
Ciber, Inc. Mr. Harold Aebi
Jack L. Cline Inter Vivos Trust Petar Alaupovic, Ph.D.
J. L. and C. N. Coffman Foundation Trust Mrs. Leota Margie Amsey
ConocoPhillips Janice B. and D. C.Anderson
Cross Family Benefit Lou E. and E. R.Andrew
Alice R. and Don W. Dahlgren The Honorable and Mrs. Bill Anoatubby
Mr. and Mrs. Louis M. Dakil Anonymous
Mrs. Nancy J. Davies APS Fire
DCP Midstream Matching Gifts Program ARINC, Inc.
Duncan Oil Properties, Inc. Mr. and Mrs. Stephen J.Arntz
Susan and Carl E. Edwards Ms.Ann Asbury
Flintco, LLC Kimberlie S. and Jason L.Ashmun
Mr. and Mrs. Mark W. Funke AT&T - Oklahoma
Ann Felton and Bob H. Gilliland Mr. Robbie Auger
Mr. David W. Gorham Mr. and Mrs. Marshall Ault
David W. Gorham Gift Fund – OCCF Jimmie Lynn and Billye Austin Foundation
Mr. John W. Griffin Cynthia B. and James H. Baker
Mr. Blake Hogan Mr. and Mrs. R. Michael Barber
HPC Investments, LLC Kay and Jim C. Bass
Leslie S. and Cliff Hudson H. Jean and Jimmy R. Bayles
Integris Health Leah A. and Dick A. Beale
Mr. and Mrs.Wm. O. Johnstone Mr. Mark L. Beffort
Janice and Dwight Journey Joanne and Vernon Belcher
E. Phil and Roberta L. Kirschner Foundation Lori and Jason Bell
Kirschner Trusts – OCCF Sheryl and Bruce T. Benbrook
Barbara N. and Edward A. Krei Mrs. Barbara B. Berry
Mr. and Mrs. R.W. Lee Fund Grant – OCCF Vickie and David L. Beyer
Debbie and Ron J. McCord Mr. and Mrs. Steve K. Bivin
Mr. Hurshel McCullough Mrs. Mary C. Blanton
Mr. Robert McLaughlin Mrs. Frances Boatright
LaDonna and Herman Meinders Mr. and Mrs. Bruce Bockus
Oklahoma Electrical Supply Company Mr. and Mrs.Tony Boghetich
Mr. Gene Rainbolt Mr. and Mrs. Darrell Boucher, Jr.
Kim and David E. Rainbolt Clara H. and John L. Bowen
Nancy and George Records Peggy and Del N. Boyles
Vicki and David B. Righthouse Barbara and Rick Braught
Mr. and Mrs. M. Scott Rund Patti K. and John A. Brett, III
SAIC Energy, Environment and Infrastructure, LLC Brett Exploration, LLC
Scaramucci Foundation Gertrud and Neil Briix

39

Ms. Susan Ross and D. Randolph Brown, Jr., M.D. Mr. and Mrs.W. J. Dillon, III
Pat H. and David J. Brown Mr. and Mrs. Jon Real Dorr
Kathleen S. and Rayford K. Brown Mrs. Beryl O. Duer
Regena A. and Brownie M. Browne Mr. Clayton Duncan
Casie and Kyle Brownlee Mr. and Mrs.Walt Duncan
Mr. Mike D. Brunsman Barbara and Bill Durrett
Judith Warkentin Bryan and Jack L. Bryan Karen and Tom L. Edgar
Ms. Marjorie L. Bryan Mrs. Cherri A. Eggleston
D. Ellen and Richard C. Burgess Mr. Jerry D. Eggleston
Christine and T. C. Burgin Mr. and Mrs. Pete Eischen
Deane W. and Randy Burnett Mr. and Mrs. Lloyd D. Eisenhour
Mrs. Betty J. Buss Mr. Jeff H. Ellard
Mr. and Mrs. David E. Byrket Nancy Payne and Robert S. Ellis
Mr. and Mrs. Robert D. Call Mr. and Mrs. Clark Ellison
Darla and Andy Campbell Joanne H. and Jerry L. Emmons
Drs. Patricia and J. Donald Capra Betty and Larry Ensz
Ms. Patsy Gaberino Carey Ethics and Excellence in Journalism Foundation
Dr. and Mrs. R. B. Carl Ms. Patricia Evans
Mr. and Mrs. B. Michael Carroll Evans and Associates Enterprises, Inc.
Mr. Gregory D. Carter Evans and Davis
Mr. and Mrs. J. D. Casey, Jr. Mr. and Mrs. C. Randolph Everest
Mr. Jeffrey F. Caughron Excalibur Oilfield Supply
Central National Bank of Poteau Mrs. Sue Phillips and Mr. James D. Fellers
Janice and Hiram H. Champlin Mr. Jarrod Lane Fergeson
Pat J. and Roy W. Chandler Ms. Cheryl Ferguson
Ms.Victoria Palmer Chase Fidelity Charitable Gift Fund
Carolyn and Bill R. Chatham First American Bank
Mrs. Jacqueline M. Cheatham First Bank and Trust Company
Dorothy N. and Max J. Claybaker First National Bank in Altus
Mr. Keith D. Clingman First National Bank of Oklahoma
Martha and Rick M. Coe Malinda Berry and Dick S. Fischer
Mrs. Carolyn P. Coffey Lisa F. Day and Kenneth Fletcher
Ms. Kathryn L. Coffman Elaine and Glenn Floresca
Lisa and Michael A. Coffman Dr. and Mrs. Robert A. Floyd
Adam Buckley Cohen Mr.Timothy E. Foley
Becky and J. Markham Collins Mr. and Mrs. Mark A. Fortuna
Suzy and Chuck E. Cotter Foundation Management, Inc.
Ms. Janet M. Cottrell Jeanne M. and Ed Fowler, Jr.
Dr. and Mrs. Louis H. Cox Mrs. Elaine L. Fransen
Cox Communications Fred Jones Family Foundation
Mr. Richard D. Craig Mrs. Josephine W. Freede
Valerie and David Craig Mrs. Barbara Fretwell
Mary Ann and Dan D. Craige Deborah K. and Richard H. Friant
Debbie and Bob E. Craine Amy and Patrick M. Gaffney
Carol and William H. Crawford Ms. Pat Gallagher
Elyse and Stanley Crites Jane Jayroe and Gerald Gamble
Russell and Hazel Crooch Endowment Fund Dr. and Mrs. John H. Gardner
Crowe and Dunlevy Debra and Robert Gholston
Mr. Les Cummings Mr. and Mrs. George T. Gibson
Mr. and Mrs.Tommy Daughtrey Harriet and Larry Gilbert
Ms. Margaret S. Davis Jean and Ben Gile
Drs. Susannah Rankin and Dean Dawson Mr. Peter D. Gill
Ms. Esther E. De Deo Mrs. Casey Lauren Gilliam
Rita and Al Dearmon Mr. and Mrs. Ralph L. Gilstrap
Myra and Sam Decker Lisa K. and Gregory F. Gisler
Brenda K. and Jerry Delozier Nancy and Jerry Glasgow
Miss Linda S. Dempsey Ms. Carol A. Glass
Paula and Lanny J. Dickmann, Jr. Mrs. Susan A. Gonzalez

40

Drs. Marie Hanigan and Gary James Gorbsky Ms. Carole C. Jemison
Danae and Evan Grace Ms. Carrie Johnson
Grant Thornton, LLP Kathy and Jim C. Johnson
Jane and Charles Gray Tom Johnson Investment Management, LLC
Mr. and Mrs. John Ray Green Lynette and Clay G. Jones
Griffin Holdings, Inc. Susan A. and John C. Jones
Mrs. Debra Gudgel Joy Enterprises
Rozella and Jim Hadwiger Dr. and Mrs. David A. Kallenberger
Mr.William A. Hadwiger Susan and Greg Kannady
Jacqueline O. and Roger V. Haglund The Honorable and Mrs. Frank A. Keating
Mr. George E. Hall Keeler-Matthews Charitable Foundation, Inc.
Halliburton Giving Choices John Kennedy Real Estate
Mr. and Mrs. Pat Hallren Mr. and Mrs. Melvin Kenney
Mr. Bret D. Hampton Mr. Robert Kent
Ms.Arthenia L. Haney Rosemary E. Kerber, Ph.D.
Hardesty Family Foundation Mrs. Lou C. Kerr
Ann and Burns Hargis Tracy A. and John J. Kidwell
D.A. and D.B. Harmon Memorial Fund – OCCF Ms. Sandra L. Kimerer
Mrs. Beverly A. Harkness Denise E. and Joseph C. King
Mr. and Mrs. Claude M. Harris, III Debra and Gary Kinslow
Mr. James H. Harrod Pam and Jim Klepper
Mrs. Maxine B. Hartman Kathryn N. Klotsch Endowment – The Baptist Foundation
Mr. Ronald F. Hartman Ms. Lisa J. Knight
Erin and Tim Hassen Ms. Rebecca F. Knight
Dawna and Marc Hatton Ladies Auxiliary to the Veterans of Foreign Wars
Debe and Rick Hauschild Mr.William Joseph Lansdown
Mr. and Mrs. Russell O. Hayes Katie Riesen and James Lathrop
Mrs. Bonnie B. Hefner Ms. Joanna L. Latting
Ms. Evelyn Helm Mrs. Mary Grace Lebeda
Ms.Audrey M. Hendershot Martha A. and Gary I. Leff
Mr. and Mrs. Frank X. Henke, III Sarah and Bruce B. Lenz
Kim and Brad Henry Mr. Herbert M. Leonard, Jr.
Myra and Gene Henry Ms. Sharon K. Lester
Mrs. Michelle J. Henry Elaine and Harrison Levy
Mrs. Lois C. Herndon Ms. LaCrecia A. Lewis
Ann D. and Michael E. Hill Jere and Al Litchenburg
Bette Jo and Frank D. Hill Mr. Dan Little
Mr. and Mrs. Ronald Hill Carolyn M. and Art A. Lockhart
Ms. Jo Ann Hintergardt Ms. Paula J. Loesch
Mr. Memphis S. Hixson Wilda and Haskell L. Looney
HoganTaylor, LLP Mr. Randy J. Ludwig
Mr.Vaughn Holcer Drs. Cristina and Florea Lupu
Ms. Nadine Holloway M and N Dealerships
The Honorable Jerome A. Holmes Sharon K. and Jim D. Mack
Home Creations, LLC Peggy and Lee Mackey
Catherine and Jerry Hoopert The Macklanburg-Hulsey Foundation, Inc.
Christine and Todd Hopeman Brenda G. and Gary M. Macri
Cathy and John M. Huber Inge and Melvin Hugh Madewell
Mr. and Mrs. Gary Huckabay Madewell and Madewell, Inc.
Annette and Larry Hull Paul Mainard Family Trust
Vicki and Carl S. Hutto Janice G. and Warren D. Majors
Idabel National Bank Joan L. and Mike J. Maly
Laura and Cecil R. Ingram Julie and William Marsh
Ms. Jolene R. Ingram Karen and Von A. Martin
Interbank Ms. Marcel A. Maupin
JAAM Trust McAfee and Taft
Dr. and Mrs. Bretton H. Jameson Mr. and Mrs. Billy Floyd McCarley
Loretta and Jerry L. Janzen Mr. and Mrs. Monty McCrary

41

Letha and Bob A. McCray Oklahoma City University
Mary H. and Tom McDowell Marilyn and John S. Oldfield, Jr.
Gigi and Rod P. McEver Mr. Jim D. Oliver
Mary O. and Mike McGraw Van and Rudy Oliver, Jr.
Kelley D. and Matt McGuire Mr. and Mrs. David Onken
Mrs. Chloe Ann McKaig Yuko and John Orban
Janis S. and Tony R. McKaig Sara and Nigel J. Otto
Mr. and Mrs. Cameron R. McLain Barbara and Kenneth Palmer
Mr. and Mrs. Mason McLain Mr. and Mrs. Bill J. Palmeter
Kathy and Scott F. McLaughlin Mrs. Pam W. Parrish
Carol and Richard L. McLennan Gayle and Richard H. Parry
Debby J. and Doug W. McQueen Ms. Shirley R. Patten
Linda and Randy N. Mecklenburg Janet S. and Larry Patterson
Linda and Ron C. Merritt Mr. and Mrs. Bond Payne
Midstate Traffic Control, Inc. Mr. Merlyn N. Pearson
Mary and Chuck Mikkelson Peck Family Charitable Foundation, Inc.
Ms. Judy A. Mikkelson Janis and Jack Perrault
Taprina K. and Kermit M. Milburn Myrla and Gary C. Pierson
Aimee E. and Kevin W. Miller Mrs. Marceline Piper
Janet F. and Gil Mitchell Ms. Sharon Piper
Susan B. and Bill A. Montgomery Mr. and Mrs. Don W. Pitman
Kevin Lee Moore, M.D. Gerry R. and Dick Pittenger
Mrs. Sarah F. Moore Estate of Sandra Pittsenbargar
Suzy and Chip Morgan Dr. and Mrs. Scott Matthew Plafker
Morgan Stanley Jackie and James S. Plaxico
Morgan Stanley Foundation Wanda S. and John R. Potts
Ms. Kimberly Morris Mrs. Marcia J. Powell
Margaret H. and Larry E. Morris Mrs. Mona Z. Preuss
Ms. Juliet Moss The Prudential Foundation
Gayle and J. Gary Mourton Mr. and Mrs.Victor W. Pryor, Jr.
Annette and Tom Mrazik Quail Creek Bank, NA
Mr. and Mrs. James A. Mueller Questcor Pharmaceuticals, Inc.
Lisa L. and Greg M. Mullen Sharon and Richard Radeka
Mr. and Mrs. James A. Mulligan, III Donna and Bill J. Ramsey
Mrs. Elois Muncy Ramsey Real Estate
J. G. Murray, III Mrs. Patsy R. Ray
Mrs.Alice B. Myers Mr. and Mrs. Steve Raybourn
Carol and Tony Nance RBG, Inc.
Cena E. and Mark S. Nault Mr. George J. Records, Jr.
Ms. Edna Irene Nedbalek Ms. Martha Ellen Records
Network for Good Mrs. Joan S. Redding
Ms. Sharon F. Neuwald Mr. and Mrs. Dee A. Replogle, Jr.
Alysa and Charles C. Newcomb Mary Jane and Gordon Richards
Mr. and Mrs. James K. Nichols Ms. Marian Riesen
Lydia D. Nightingale, M.D. Mr. and Mrs. Howard Ring
Dr. Linda B. Nimmo Mrs.Willa Gayle Ring
Ms. Joann L. Nitzel Mr.Andy Roberts
Mr. and Mrs. Dennis G. Noble Mr. Phillip Roberts
Mr. Lloyd Noble, II Mr. Richard D. Roberts
Mr. R. David Nordyke Mr. and Mrs. C.W. (Bill) Robertson, Jr.
Ms. Julie Norman Mr. and Mrs. Fred J. Robertson
Sara and Rob Northwood Mr. Craig Roddy
Diana and David O’Daniell Ms. Beverly Rodgers
Janet K. and Tal Oden Ms. Sarah Jane Rodgers
Mr. David P. Odom Mr. Robert L. Rogers
Beth and P. B. Odom, III Rogers and Bell
Mrs. Frances W. O’Hornett Mr. and Mrs. Patrick Turner Rooney
Oklahoma Association of Mothers’ Clubs Grant Fund Ms. Debbie Rose

42

Sharon and Gary Roth Mr. and Mrs. John A.Trigg
Lynne and Bob Rowley Dr. and Mrs. Stephen E.Trotter
Ms. Kathryn R. Ryan Truist, Inc.
Mr. and Mrs. Richard N. Ryerson Twin Franchise, LLC
Mrs. Dorothy F. Sales Lori and Ty A.Tyler
Mrs. Patricia P. Savage Ms. Jo Lou Tyson
Dr. and Mrs. Olaseinde I. Sawyerr UMB Bank, N.A.
Barbara and John Schaefer Bonnie and Mickey Vanderwork
Ethel M. and Paul Schiller Mr. Benjamin Vannier
Dr. Clyde H. Schoolfield, Jr. Ms. Margaret A.Vater
Schraad Enterprises, LLC Penny and Russell Voss
Sue and Doug Schrag Marsha and John N.Waldo
Mr. and Mrs. Phillip Schultz Mr. and Mrs. Gary V.Walker
Ms. Sue Seymour Mrs. Margie Ware
Mr. Rob Shaff Donna K. and Allyn G.Warkentin
Pam and Bill F. Shdeed Mr. and Mrs. James J.Wasson
Rebecca A. and Kirby G. Shelton Dr. Gregory L.Watkins
Tenna M. and Greg S. Shepherd Gloria A. and Marcus L.Weatherall, Sr
Marilyn K. and Rex A. Sheppard Ms. Margaret A.Weddle
Jeannette and Richard L. Sias Barbra B. and Kenneth A.Weikel
Mr. Richard M. Singer Carmalieta and Dan Wells
Mrs. Margaret D. Smith Mr. and Mrs. Steve E.Wells
Mr. Ralph C. Smith Trish A. and Jarrod Welsh
Joan and John F. Snodgrass Weokie Credit Union Foundation
Southwestern Stationery and Bank Supply, Inc. Mr. and Mrs. Royce H.Wieden
Mr. Neil Spaeth Wiens Investments, LLC
Katherine P. and John S. Spaid Mr. and Mrs. G. Rainey Williams, Jr.
Mr. and Mrs. Clyde W. Spence Mr. Jimmy H.Williamson
Jay and Millie Stafford Margaret B. and John L.Williford
Mary E. and Craig H. Stanley Willow Road Christian Church
Mr. Kenneth A. Stanley Gara and Russ Wilsie
Mr. and Mrs. Danny L. Stansbury Ms.Toni N.Wizenberg
Linda and Frederic W. Stearns Cynthia T. and Jim C.Wolfe
Ms. Karen Stephenson Conna D. and Paul S.Woolsey
The Stillwater National Bank and Trust Company Camilla Wright and Dick Wright
Krista M. Jones, DDS, and Mr. Craig Stinson Mr. and Mrs. R. Deane Wymer
The Stock Exchange Bank Dr.William B.Wynn
Mrs. Phyllis Jarnagin Stough Ms. Darlene Wynne
The Stracke-Styron Family Lijun Xia, M.D., Ph.D.
Mr. and Mrs. Coy Sullivan Dr. and Mrs. James J.Yoch
Miss Joy Sullivan Mr. John M.Yoeckel
Julie and Mark S. Svoboda Carol and Tim Zaloudek
Margaret and Ross O. Swimmer Jan and Don Zimmerman
Mr. and Mrs. Barry Switzer
Ms. Dawn Tamir $500 - $999
Glenna G. and Richard I.Tanenbaum
Ms. Jane Taylor Carolyn A. and Richard M.Adkins
Lisa R. and Tim W.Teske Kathy and Joe Adwon
Ms. Lawanda Thetford Mr. and Mrs. Paul W.Albers
Jane and LeRoy Thompson Anonymous
Linda F.Thompson, Ph.D. Autodesk
Cheryl J. and Phillip R.Thompson Mr. and Mrs. Bob M. Barnard
Jackie and Robert C.Tilghman Shirley and Gary B. Barnett
Laura M. and William J.Toellner Tina A. and Elby J. Beal
Beth J. and Rheal A.Towner Ruth L. and Gary D. Beatie
Mr. and Mrs. Ron E.Townsdin Beau’s Wine Bin and Spirit Shoppe
Mary L. and Larry B.Trachtenberg Beaustack Enterprises, Inc.
Jacqueline F. and Dennis Trepangier Mrs.Alma G. Betchan
Mr. and Mrs. Michael Biddinger

43

Rebecca S. and Lowry Blakeburn, II Teresa and Robert Hamra
Mrs. Coyla J. Bowden Mrs. Betty Harding
Bowers Construction Company Hartzog, Conger, Cason and Neville
Karen W. and Jeff J. Bowser Heiman Family Foundation
Mr. Marshall Brackin Mr.Terry L. Helms
Ms. Doris Brehm Mr. and Mrs. Gerry L. Hendrick
The Honorable and Mrs.Tom R. Brett Mr. Richard C. Henry
Newie and Mark Brinker Mr. and Mrs. Donnie Holloway
Dr. Regina A. Buckley Mr. and Mrs. John G. Hronopulos
Michelle M. and William Calvo Mr. and Mrs. Donald E. Hubbard
Ginny B. and Peter B. Carl Mr. Ronald G. Jacob
Hong Chen, Ph.D. Mr. and Mrs. Donald E. Jeffers
Mr. Kyle Clayton Mr. Gerald H. Jobe
Mr. and Mrs. Clay D. Clinesmith Mrs. Karen S. Johnson
Mr. and Mrs. John J. Coates, Jr. Carol A. and Russel C. Johnson
Jim and Teresa Coffman Mr. and Mrs.William R. Johnson
Mrs. Ernestine E. Cook Sandra S. and Gail P. Jones
Mr. and Mrs. George Corkins Mr. Russell W. Jones
Kathleen and Jake Coughlan Joyce A. and Don L. Keel
Mr. and Mrs. S.A. Crank Marilyn and Larry J. Kennedy
Mr. Harold L. Crites Jacquelyn D. and August M. Khilling
Barbara and Dean A. Cunningham Melanie and Paul W. Kincade
Ms. Mollyann Cypert Mrs. Opal C. King
Jacque M. and Rick M. Dean Caroline and Mike T. Kinter
Mr. and Mrs. Charles R. DeLong Ms. Rebecca Knight
Arloene and Gilbert G. Dick Mr. and Mrs. Kenneth L. Kofoed
Mr. and Mrs. Mark A. Dick KSWO Television Company, Inc.
Mr. and Mrs.William F. Dost, Jr. Kim and Mark Lauer
Mrs. Marilyn A. Doty Lawton Cablevision, Inc.
Aleen and Clarence C. Drumeller Miss Darlene Lewis
Mr. and Mrs.Andrew J. Dubois Kathleen Lister Fund – OCCF
Mrs. Nancy Jo Ellis Loretta M. and John C. Long
Susan L. and Steve Esco Mr. and Mrs. Karen and Donny Longest
Mrs.Ann Farmer The Honorable Claire V. Eagan and Mr.Anthony J. Loretti, Jr.
Debbie and Larry Fenity Ms. Lori Lumsden
Mr.Thomas A. Fitzgerald Michele and Mike L. Mackey
Lynn S. and Creed L. Ford, III Ms. Judith H. Malarkey
Mary B. and William J. Fors Ms. Billie W. Marcoux
Dorothea French Fund Maud Public Schools
Ms. Lisa M. Funderburg Mr. and Mrs. Dennis M. McGrath
Mr. and Mrs. Ernest Gabriel Judy A. and Gene McKown
Mr. and Mrs. Byron Gambulos Mr. and Mrs. Edwin McQuigg
Marilynn H. and Paul F. Gassen Mr. Gary W. Melsby
Mr. and Mrs. James N. Gibson Merco Energy LLC/Elizabeth M. Coe
Ms.Andrea Gift Billie L. and V. David Miller
Mr. and Mrs. Olin Gilbert Miller Family Foundation
Mr. and Mrs. Steve Glasser My Tribute Gift Foundation, Inc.
Ms. Patricia J. Goode National Council of University Research Administrators
Ms. Sharon J. Bell and Mr. Gregory A. Gray Mr. and Mrs. Paul F. Nighswonger
Lisa G. and Jeff Greenlee The Honorable and Mrs. Ron Norick
Thadda and Sid M. Groom, Jr. Norick Investment Company Advised Fund – OCCF
Mrs. Martha C. Grubb Mrs. Jo Ann Oliver
Jayne R. and Les Hackworth OMRF Research Fund – OCCF
Estate of Marilyn Hafer Ms. Licia M. Pallatto
Ms. Elaine F. Hahn Mr. and Mrs. Roy G. Paston
Carole and Boots Hall Caroline and Guy Patton
William H. Hall, M.D. Barbara J. and Robert W. Penick
Ms. Pauline G. Hamilton Pharmacy Providers of Oklahoma, Inc.

44

Ms. Laura L. Pompa Discoveries Campaign - Campus
Bridget and Paul Poputa-Clean Expansion - Phase I and II
Mr. and Mrs. Harold G. Powell
Mr. Mark H. Price Now in Phase II, we have secured more than $9 million toward our
Kathryn M. and Phillip E. Rattan goal of $40 million to help recruit new world-class scientists to OMRF.
Ms.Angela Reynolds Achieving this goal will ensure that Oklahoma stays on the leading edge
Carol A. and Mike L. Rhodes of biomedical research.
Sally T. and John S. Riley
Linda A. and John C. Roach $5,000,000 and above
Ms. Susan Rodgers
Mr. and Mrs. Michael S. Samis Association of Central Oklahoma Governments
Mrs. Susan Freeland and Mr. Ken Schley Chapman Charitable Trusts
Pat A. and Eldon H. Schuessler E. L. and Thelma Gaylord Foundation
Dr. Hakeem Shakir National Institutes of Health
Ms. Pamela Sharp Samuel Roberts Noble Foundation, Inc.
Mr. and Mrs. John A. Shelley State of Oklahoma Opportunity Fund
Shelter Insurance Foundation
Sigma Nu Pledge Class of 1964 $1,000,000 - $4,999,999
Dr. Paul and Dr.Amalia Silverstein
Nancy D. and Jim Simmons Mary K. Chapman Foundation
Gerald T. Skinner Mr. David J. Chernicky
Dr. and Mrs. Joseph L. Skinner Hardesty Family Foundation
Dr. and Mrs. Bob Smith Hocker Foundation
JoAnn and Kenneth C. Smith Inasmuch Foundation
Southern Oklahoma Cutting Horse Association J. E. and L. E. Mabee Foundation, Inc.
Mr. and Mrs. Kenneth Steele Masonic Charity Foundation
Susan and Owen Sutter Katie and Aubrey McClendon
Janet L. and Charles L.Talley New Source Energy Corporation
Ms. Margaret R. Dawkins and Mr. Kenneth David Taylor Presbyterian Health Foundation
Marlene and Charles L.Tefertiller Rainbolt Family
Mr.Alvin L.Thomas, Jr. Records-Johnston Family Foundation, Inc.
Thomas N. Berry & Company Sarkeys Foundation
Mr. Mike Thompson Anne and Henry Zarrow Foundation
Janet and Sammy Todd
Joyce F. and Lynn Treece $500,000 - $999,999
Judy and Ronald S.Turner
Tami and Brad Vaughan Choctaw Nation of Oklahoma
Heather and Robert R.Vick Virginia and John Groendyke
The Vision Bank McCasland Foundation
Mitzi and Philip Walker Puterbaugh Foundation
Judy F. and Gene Walters Peggy and Charles Stephenson Cancer Center
Michelle D. and Lee R.Walther
Waters Charitable Foundation $100,000 - $499,999
Ms. Mary Lynn West
Westminster Middle School 241 Event Proceeds - Multiple Sclerosis
Jan K. and Jim C.Wittrock Ann Simmons Alspaugh
Ms. Louise Wolff Anonymous
Cheryl W. and Clyde F.Wootton Chesapeake Energy Corporation
Mr. and Mrs. Dick Workman ConocoPhillips
Sallie and John A.Wright The Dillingham Family
Ms. Donna J.Wyskup Drs. Naomi and Chuck Esmon
Mr. and Mrs. James G.Young William Randolph Hearst Foundation
Ms. Linda R.Young The Kerr Foundation, Inc.
Ms. Betty Zuker Patti and Don J. Leeman
Elaine and Harrison Levy
Lou Ann and Jim Morris
MS Bridge Fund
National Multiple Sclerosis Society
Glenn W. Peel Foundation
Susan and Stephen Prescott
Robert Glenn Rapp Foundation
Dr. John H. Saxon, III

45

FSaciceunlttiyfic Advanced Magnetic Cardiovascular
Resonance Center Biology

Rheal A. Rodger
Towner, Ph.D. P. McEver, M.D.

Associate Member Member and Program Chair



Arthritis and Farhat Florea
Clinical Immunology Husain, M.D. Lupu, Ph.D.

Judith A. Associate Member Member
James, M.D., Ph.D.

Member and Program Chair
Courtney Gray Lijun
Montgomery, Ph.D. Xia, M.D., Ph.D.

Patrick Associate Member Member
Gaffney, M.D.

Member
Gabriel Hong
Pardo, M.D. Chen, Ph.D.

Swapan K. Associate Member Associate Member
Nath, Ph.D.
Member

Robert Courtney
Axtell, Ph.D. Griffin, Ph.D.
Robert H.“Hal”
Scofield, M.D. Assistant Member Associate Member

Member

Susan Jana
Kovats, Ph.D. Barlic-Dicen, Ph.D
Kathy L.
Sivils, Ph.D. Assistant Member Assistant Member

Member

Ira N. Satish
Targoff, M.D. Srinivasan, Ph.D.
Marta
Alarcón-Riquelme, M.D., Ph.D. Assistant Member Assistant Member

Associate Member

Katherine Clinical Pharmacology
Thanou, M.D.
Eliza Joan T.
Chakravarty, M.D. Assistant Member Merrill, M.D.

Associate Member Member and Program Chair

Jonathan D.
Wren, Ph.D.
Umesh Coagulation Biology
Deshmukh, Ph.D. Assistant Member Laboratory

Associate Member Charles T.
Esmon, Ph.D.

Member
Darise
Farris, Ph.D.

Associate Member



46

Cell Cycle and Immunobiology and Cancer
Cancer Biology
David Carol F.
Gary J. Jones, Ph.D.
Gorbsky, Ph.D. Webb, Ph.D.
Member and Program Chair
Member and Program Chair Member



Dean Paul W. Kincade, Ph.D. José
Dawson, Ph.D.
Member and Vice President Alberola-Ila, M.D., Ph.D.
Member
of Research Associate Member


Roberto
Pezza, Ph.D. Mark Lorin
Coggeshall, Ph.D. Olson, Ph.D.
Assistant Member
Member Assistant Member


Susannah
Rankin, Ph.D. Xiao-Hong Weidong
Sun, Ph.D. Wang, Ph.D.
Assistant Member
Member Assistant Member


Christopher L.
Sansam, Ph.D. Linda
Thompson, Ph.D.
Assistant Member
Member



Free Radical Biology and Aging Genetic Models
of Disease
Luke I. Timothy M.
Szweda, Ph.D. Griffin, Ph.D. James B.
Rand, Ph.D.
Member and Program Chair Assistant Member
Member and Program Chair

Holly Van
Remmen, Ph.D. Kenneth M.
Humphries, Ph.D. Kenneth G.
Member Miller, Ph.D.
Assistant Member
Associate Member


Hui-Ying
Michael T. Lim, Ph.D. Distinguished
Kinter, Ph.D. Career Scientists
Assistant Member
Associate Member Morris
Reichlin, M.D.


Scott M.
Plafker, Ph.D., R.Ph. Jordan J. N.
Tang, Ph.D.
Associate Member


Fletcher B.
Experimental Taylor, Jr., M.D.
Therapeutics Laboratory

Robert A.
Floyd, Ph.D.

Member



47

Board of Directors

Greg Allen J.Walter Duncan, IV Randy Hogan Pat Rooney

Charlottesville,VA Edmond Edmond Oklahoma City

Ann Alspaugh* William Durrett* The Hon. Jerome Holmes Robert Ross

Oklahoma City Oklahoma City Oklahoma City Oklahoma City

The Hon. Bill Anoatubby The Hon. Claire Eagan Cliff Hudson Michael Samis

Ada Tulsa Oklahoma City Oklahoma City

James Bass Carl Edwards Brett Jameson, M.D. John Saxon, III, M.D.

Oklahoma City Oklahoma City Stillwater Muskogee

Sharon Bell Patricia Evans William O. Johnstone Paul Schulte

Tulsa Ponca City Oklahoma City Kingfisher

Bruce Benbrook C. Randolph Everest* Lou Kerr John Snodgrass*

Woodward Oklahoma City Oklahoma City Ardmore

Lance Benham, III Christy Everest Harrison Levy, Jr. Phyllis Stough

Oklahoma City Oklahoma City Oklahoma City Oklahoma City

Elizabeth Blankenship* Ann Felton Dan V. Little Ross Swimmer

Oklahoma City Oklahoma City Oklahoma City Tulsa

Jil Boghetich C. Kendric Fergeson Bill Loughridge, M.D. Becky Switzer

Oklahoma City Altus Tulsa Norman

Barbara Braught Larry Ferree Gerald Marshall* The Hon. Steven Taylor

Duncan Oklahoma City Oklahoma City McAlester

Randy Brown, M.D. Malinda Berry Fischer Jack McCarty Betsy Thorpe

Oklahoma City Stillwater Newkirk Oklahoma City

Bill Burgess, Jr. Barbara Fretwell Frank McPherson Greg Walton, M.D.

Oklahoma City Oklahoma City Oklahoma City Oklahoma City

Ellen Burgess Mark Funke James Morris, II Lew Ward

Tulsa Edmond Oklahoma City Enid

Merrill Burruss, Jr.* Gerald Gamble James Mueller Rainey Williams, Jr.

Geary Oklahoma City Oklahoma City Oklahoma City

William Cameron John Green* J. Larry Nichols Deane Wymer

Oklahoma City Oklahoma City Oklahoma City Fairview

C. Michael Carolina John Griffin Richard Parry *Life Director

Edmond Muskogee Oklahoma City

Mike Carroll Martha Griffin Rebecca Patten

Edmond Muskogee Norman

Len Cason (Chair) Virginia Groendyke S. Bond Payne, Jr.

Oklahoma City Enid Oklahoma City

Hiram Champlin Jacqueline Haglund Gary Pierson

Dallas,TX Tulsa Oklahoma City

Elizabeth Merrick Coe* Brooks Hall, Jr. Donne Pitman

Oklahoma City Oklahoma City Tulsa

J. Markham Collins, Ph.D. V. Burns Hargis Harold Powell*

Tulsa Oklahoma City Norman

Louis Cox, M.D. William Hawley, M.D. David Rainbolt

Oklahoma City Oklahoma City Oklahoma City

William H. Crawford Kim Henry H. E. Rainbolt*

Frederick Edmond Oklahoma City

Ramsey Drake Robert Henry Dee Replogle, Jr.

Oklahoma City Oklahoma City Oklahoma City

48